Your browser doesn't support javascript.
loading
Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.
Brüggen, Marie-Charlotte; Walsh, Sarah; Ameri, M Milad; Anasiewicz, Natalie; Maverakis, Emanual; French, Lars E; Ingen-Housz-Oro, Saskia; Abe, Richiiro; Ardern-Jones, Michael; Assier, Haudrey; Barbaud, Annick; Bensaid, Benoit; Bernal, William; Bernier, Claire; Brassard, Alain; Brezinová, Eva; Cabañas, Rosario; Cardones, Adela; Chu, Chia-Yu; Chua, Ser-Ling; Descamps, Vincent; Didona, Biagio; Divito, Sherrie Jill; Dodiuk-Gad, Roni; Elman, Scott; Gaspar, Krisztian; Mortz, Charlotte G; Hama, Natsumi; Lee, Haur Yueh; Horváth, Barbara; Jörg, Lukas; Kaffenberger, Benjamin H; Kucinskiene, Vesta; Lebrun-Vignes, Bénédicte; Lehloenya, Rannakoe J; Meyersburg, Damian; Micheletti, Robert; Milpied, Brigitte; Miyagawa, Fumi; Mostaghimi, Arash; Nägeli, Mirjam; Naldi, Luigi; Oppel, Eva; Phillips, Elizabeth J; Pirani, Tasneem; Ranki, Annamari; Mälkönen, Tarja; Rosenbach, Misha; Salavastru, Carmen; Staumont-Salle, Delphine.
Afiliación
  • Brüggen MC; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Walsh S; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Ameri MM; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
  • Anasiewicz N; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Maverakis E; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • French LE; Department of Dermatology, King's College Hospital, London, England, United Kingdom.
  • Ingen-Housz-Oro S; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Abe R; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
  • Ardern-Jones M; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Assier H; Department of Dermatology, University of California, Davis, Sacramento, California.
  • Barbaud A; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Bensaid B; Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
  • Bernal W; Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida.
  • Bernier C; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Brassard A; Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France.
  • Brezinová E; Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Cabañas R; Univ Paris Est Créteil EpiDermE, Créteil, France.
  • Chu CY; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Chua SL; Department of Dermatology, Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, England, United Kingdom.
  • Descamps V; Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France.
  • Didona B; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique, AP-HP Sorbonne Universite, Tenon Hospital, Department of Dermatology and Allergology, Paris, France.
  • Divito SJ; Department of Dermatology, Lyon Natecia Hospital, Lyon, France.
  • Dodiuk-Gad R; Liver Intensive Therapy Unit, King's Critical Care, King's College Hospital, London, England, United Kingdom.
  • Elman S; Department of Dermatology, University Hospital Nantes, Nantes, France.
  • Gaspar K; Department of Dermatology, University of California, Davis, Sacramento, California.
  • Mortz CG; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Hama N; Department of Dermatovenereology, St Anne's Faculty Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Lee HY; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
  • Horváth B; PIELenRed Consortium, Madrid, Spain.
  • Jörg L; Center for Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain.
  • Kaffenberger BH; Department of Dermatology, University of Kansas, Kansas City.
  • Kucinskiene V; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lebrun-Vignes B; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Lehloenya RJ; Department of Dermatology, University of California, San Francisco.
  • Meyersburg D; Department of Dermatology, Bichat-Claude Bernard Hospital, Paris Diderot University, Paris, France.
  • Micheletti R; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.
  • Milpied B; Center of Rare Diseases IDI-IRCCS, Rome, Italy.
  • Miyagawa F; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mostaghimi A; Department of Dermatology, Emek Medical Center, Afula, Israel.
  • Nägeli M; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Naldi L; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Oppel E; Department of Dermatology, Miller School of Medicine, University of Miami, Miami, Florida.
  • Phillips EJ; Department of Dermatology, University of Debrecen, Debrecen, Hungary.
  • Pirani T; Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Ranki A; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Mälkönen T; Department of Dermatology, Singapore General Hospital, Singapore, Singapore.
  • Rosenbach M; Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Salavastru C; Division of Allergology and Clinical Immunology, Department of Pneumology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Staumont-Salle D; Department of Dermatology, The Ohio State University, Columbus, Ohio.
JAMA Dermatol ; 160(1): 37-44, 2024 Jan 01.
Article en En | MEDLINE | ID: mdl-37966824
ABSTRACT
Importance Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment.

Objective:

To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. Design, Setting, and

Participants:

The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022. Main Outcomes/

Measures:

The degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1.

Results:

In the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup. Conclusions and Relevance This Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Eosinofilia / Síndrome de Hipersensibilidad a Medicamentos Idioma: En Revista: JAMA Dermatol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Eosinofilia / Síndrome de Hipersensibilidad a Medicamentos Idioma: En Revista: JAMA Dermatol Año: 2024 Tipo del documento: Article